Bevacizumab (Avastin®)

DRUG3 trials

Sponsors

Sanofi, University of Colorado, Denver, Hanny Al-Samkari, MD

Conditions

Hereditary Hemorrhagic TelangiectasiaOvarian CancerRadiation Necrosis

Phase 2

TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

CompletedNCT00296816

SanofiOvarian Cancer

Start: 2006-03-31End: 2011-08-31Updated: 2012-08-23

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Active, not recruitingNCT04404881

Hanny Al-Samkari, MDHereditary Hemorrhagic Telangiectasia

Start: 2020-11-23End: 2027-02-01Updated: 2026-03-27

Unknown Phase

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

TerminatedNCT01201850

University of Colorado, DenverRadiation Necrosis

Start: 2010-06-28End: 2016-08-04Updated: 2021-05-19